Johnson & Johnson Announces New Data on RYBREVANT and LAZCLUZE Combination in NSCLC

Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study showing that RYBREVANT plus LAZCLUZE significantly reduces EGFR- and MET-driven resistance compared to osimertinib in EGFR-mutated non-small cell lung cancer patients. The combination also extends survival and reduces common EGFR and MET resistance mutations. The data build on the combination's previously reported overall survival benefit and underscore its potential to change the biology of the disease by preventing acquired resistance.